CAS 2559704-23-1
:Research Grade Emfizatamab (DHD10809)
Description:
Research Grade Emfizatamab (DHD10809), with the CAS number 2559704-23-1, is a monoclonal antibody designed for therapeutic applications, particularly in the field of oncology. As a humanized IgG1 antibody, it targets specific antigens on cancer cells, facilitating immune-mediated destruction of these cells. Its mechanism of action typically involves binding to the target antigen, which can trigger various immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Emfizatamab is characterized by its high specificity and affinity for its target, which enhances its therapeutic efficacy while minimizing off-target effects. In research settings, it is often utilized to study tumor biology and the immune response to cancer. The substance is usually supplied in a sterile, lyophilized form, requiring reconstitution before use in experiments. As with many monoclonal antibodies, stability, storage conditions, and handling protocols are critical to maintain its integrity and functionality for research purposes.
- Research Grade Emfizatamab
- Research Grade Emfizatamab (DHD10809)
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
Emfizatamab
CAS:<p>Emfizatamab (GNC-038) is a tetravalent antibody that activates CD3 and 4-1BB on T cells while targeting CD19 or PD-L1 on tumor cells, resulting in T-cell-mediated cytotoxicity against human leukemia and lymphoma cells.</p>Color and Shape:Liquid
